Sun Pharma
Tracked across 70 events · 3210 articles · First seen Jan 07, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Sun Pharma Ltd. announced the schedule for its second quarter 2026 financial results release and subsequent conference call and webcast. This event is a routine financial disclosure for the company.
Jun 18, 2026 · 6 articles
Business
Impact: Sun Pharma acquired Emalex Biosciences, strengthening its late-stage neuroscience pipeline with Ecopipam and advancing its Pivot to Growth strategy. This acquisition is expected to support near- and long-term growth for Sun Pharma.
Jun 10, 2026 · 8 articles
Business
Impact: Sun Pharma Ltd. is participating in the Goldman Sachs Global Healthcare Conference, providing an opportunity to present its strategies and outlook to investors and the financial community.
Jun 01, 2026 · 6 articles
Business
Impact: Sun Pharma launched AHZANTIVE, a biosimilar to Eylea, in Europe, expanding its biosimilars portfolio and presence in ophthalmology, aligning with its Pivot to Growth strategy.
Jun 04, 2026 · 7 articles
Business
Impact: Teva is the developer of TEV-408 and announced the Phase 2b advancement, which supports its pipeline and growth strategy, positively impacting its stock.
Jul 07, 2026 · 7 articles
Business
Impact: Teva secures exclusive global rights to commercialize the biosimilar, advancing its Pivot to Growth strategy and expanding its biosimilars pipeline.
Jul 09, 2026 · 14 articles
Regulatory
Impact: Sun Pharma received regulatory approval to market generic semaglutide in South Africa, its second market after India, enhancing its product portfolio and access to the diabetes treatment market.
Jul 15, 2026 · 8 articles
Business
Impact: Sun Pharma reported a 27% rise in Q1 net profit and 10.5% revenue growth, driven by India and innovative medicines, while US generics declined. The company is progressing on its Organon acquisition, expected to close in early 2027.
Jul 31, 2026 · 7 articles
Regulatory
Impact: Sun Pharma initiated the precautionary withdrawal of multiple eye drop products in India due to a contamination scare, instructing distributors to stop billing and return stocks. This action may lead to short-term revenue loss and reputational risk, but the company's emphasis on patient safety could help maintain trust.
Aug 01, 2026 · 7 articles
Regulatory
Sun Pharma has filed a motion in U.S. federal court in Philadelphia to prevent insurer Humana from telling jurors that Teva is an Israeli company during an upcoming drug price-fixing trial. Teva argues that strong…
Impact: Teva is the defendant seeking to exclude references to its Israeli origin to ensure a fair trial. The outcome could affect its legal exposure and reputation.
Aug 06, 2026 · 6 articles
Regulatory
Sun Pharma announced that the United States — Food and Drug Administration accepted its New Drug Application for ecopipam, a first-in-class D1 dopamine receptor antagonist for pediatric Rett syndrome, and granted Priority Review with a…
Impact: Teva is the developer and sponsor of ecopipam; the FDA acceptance advances its neuroscience pipeline and growth strategy, with shares rising in pre-market trading.
Aug 19, 2026 · 7 articles
Regulatory
Impact: Sun Pharma>>> is responsible for the commercialization of AVT16 under a partnership with Alvogen>>>, which could expand its product portfolio if approved.
Jun 08, 2026 · 11 articles
Business
Impact: Sun Pharma>>> is partnered with Alvogen>>> for the commercialization of AVT05 and AVT06. The resubmission of BLAs by Alvogen>>> is a positive development for Sun Pharma>>> as it moves closer to potentially commercializing these biosimilars.
Jun 04, 2026 · 10 articles
International
Impact: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
Tech
Impact: Sun Pharma is one of the 23 leading pharmaceutical companies included in the Indian Pharmaceutical Alliance, which is a partner in the Indian AI Research Organization (IAIRO) project.
Dec 30, 2025 · 7 articles
Business
Impact: Sun Pharma, a generic drug manufacturer, settled with UroGen Pharma Ltd. to receive a non-exclusive license to sell a generic version of Jelmyto starting September 15, 2030. This will introduce future competition for UroGen Pharma Ltd.'s product.
Jun 14, 2026 · 6 articles
Business
Impact: Sun Pharma was among the winning stocks, contributing to the overall market gains.
Jul 03, 2026 · 7 articles
Regulatory
Impact: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
Business
Impact: Sun Pharma was among the laggards in the Sensex.
Jul 17, 2026 · 20 articles
Business
On August 19, 2026, Indian benchmark indices Sensex and Nifty fell for the fourth and seventh consecutive sessions respectively, as elevated crude oil prices and the expiry of the temporary 60-day US-Iran ceasefire without a…
Impact: Gained, being among the winners.
Aug 19, 2026 · 6 articles
Business
Impact: Sun Pharma is among the Indian generic drugmakers expected to introduce lower-priced versions of semaglutide after Semaglutide's patent expires.
Nov 11, 2025 · 6 articles
Business
Impact: Sun Pharma's Leqselvi is a competitor JAK inhibitor; potential competitive pressure from bempikibart.
Jul 13, 2026 · 6 articles
International
Impact: Gained as a top gainer.
Jul 06, 2026 · 105 articles
Regulatory
Rackspace Technology, Inc. faces a securities fraud class action lawsuit alleging that it made materially false and misleading statements regarding its enterprise AI efforts and their impact on its profitable Private Cloud segment. The class…
Impact: Teva is mentioned only as a past success for BFA, not directly related to the Rackspace case. It has no direct impact from this event.
Jul 13, 2026 · 220 articles
Domestic
Impact: Among laggards, possibly due to profit booking.
Aug 03, 2026 · 20 articles
Regulatory
Coastal Financial Corporation, a bank holding company based in Everett, Washington, reported a GAAP net loss of $42.1 million, or $2.76 per diluted share, for Q2 2026, driven by a $68.8 million pre-tax credit expense…
Impact: Teva is mentioned only as a past success for Bleichmar Fonti & Auld LLP, having recovered $420 million. It is not directly involved in this event.
Aug 04, 2026 · 25 articles
Regulatory
NRx Pharmaceuticals, Inc. announced that the U.S. United States — Food and Drug Administration (FDA) has completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine. The company will host…
Impact: Teva is mentioned as the former employer of Chaim Hurvitz, providing context to his background but not directly involved in this event.
Aug 07, 2026 · 6 articles
Regulatory
Impact: Sun Pharma is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered a significant amount.
May 12, 2026 · 65 articles
Business
Impact: Sun Pharma is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered a significant amount in a separate legal action.
Aug 19, 2025 · 20 articles
Regulatory
Impact: Sun Pharma is mentioned as a past success for Bleichmar Fonti & Auld LLP, having recovered $420 million.
Nov 13, 2025 · 51 articles
+ 40 more events
View on Dashboard
100
United States — Food and Drug Administration accepted NDA Sun PharmaFDA Accepts Teva Ecopipam NDA
80
Sun Pharma requested court order HumanaTeva seeks to hide Israel...
60
Humana filed counter-motion Sun PharmaTeva seeks to hide Israel...
Astec LifeSciences
competitor
↔
Sun Pharma
Sun Pharma competes directly with Astec LifeSciences and its related entities in
Abbott Laboratories
competitor
↔
Sun Pharma
Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories
Astec LifeSciences
competitor
↔
Sun Pharma
Astec LifeSciences, alongside its associated life sciences brands, operates as a
Abbott Laboratories
competitor
↔
Sun Pharma
Abbott Laboratories competes directly with Sun Pharma in the global pharmaceutic
+ 20 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Sun Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard